Association of Pathological Complete Response with Long-Term Oncological Outcomes After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Retrospective Analysis of 327 Patients
Aug 2026· Medicina· Vol 62· 0 citations· 26 references
Medicine
TL;DR
PCR following neoadjuvant therapy in patients with LARC is associated with favorable long-term oncological outcomes, and this findings support the prognostic relevance of pCR while emphasizing the contribution of baseline disease characteristics to long-term survival.
Abstract
Background and Objectives: While total neoadjuvant therapy (TNT) is increasingly adopted, conventionally fractionated neoadjuvant chemoradiotherapy (CRT) followed by surgery remains the standard approach for many patients with locally advanced rectal cancer (LARC). Tumor regression following neoadjuvant therapy varies, potentially influencing oncologic outcomes. This study aimed to evaluate the association between pathological complete response (pCR) and long-term overall survival (OS) and disease-free survival (DFS) in patients with LARC undergoing neoadjuvant therapy and surgery. Materials and Methods: This retrospective study included patients who received long-course radiotherapy with concurrent capecitabine, followed by curative-intent surgery between January 2006 and January 2017. Patients were stratified according to the presence or absence of pCR. The primary outcomes were 5-year OS and DFS; secondary outcomes included locoregional recurrence and distant metastasis rates. Results: Among 327 patients, 47 (14.4%) achieved pCR. Patients with pCR had significantly lower pretreatment clinical T stage (p = 0.033) and clinical N stage (p = 0.049) and were more frequently classified as clinical stage II (55.3% vs. 40.0%, p = 0.049). Long-term oncological analyses included 322 patients after the exclusion of five early postoperative deaths. Locoregional recurrence (6.4% vs. 9.8%, p = 0.59) and distant metastasis (10.6% vs. 20.0%, p = 0.15) were numerically less frequent in the pCR group but did not differ significantly. Five-year OS was 91.5% in the pCR group and 73.1% in the non-pCR group (log-rank p = 0.027), while 5-year DFS was 85.1% and 61.5%, respectively (log-rank p = 0.008). After adjustment for age, sex, tumor location, pretreatment clinical T and N stage, and the CRT-to-surgery interval, pCR remained associated with improved DFS (adjusted HR 0.542, 95% CI 0.296–0.994, p = 0.048). In contrast, the association between pCR and OS was attenuated and did not reach statistical significance (adjusted HR 0.575, 95% CI 0.305–1.083, p = 0.087). Conclusion: pCR following neoadjuvant therapy in patients with LARC is associated with favorable long-term oncological outcomes. After adjustment for baseline clinical characteristics, pCR remained associated with improved DFS, whereas its association with OS was attenuated and did not reach statistical significance. These findings support the prognostic relevance of pCR while emphasizing the contribution of baseline disease characteristics to long-term survival.
BACKGROUND
Current National Comprehensive Cancer Network (NCCN) guidelines recommend omission of adjuvant therapy in esophageal cancer patients achieving pathological complete response (pCR) following neoadjuvant treatment. However, 20-40% of these patients experience disease recurrence, potentially indicative of resid...
Zi-An Zhang, Jun-Feng Liu, Jun-Hong Liu et al.· European Journal of Surgical...· 0 citations
Objective: To evaluate the clinical and pathological response rates to long-course Concurrent Chemoradiation therapy in rectal cancer patients, including the rate of conversion to resectable disease and tumor size reduction.
Study Design: Prospective Observational Study.
Place and Duration of Study: Department of Radia...
Shahzeb Jawed, Salman Arif, Z. Alvi et al.· Pakistan Armed Forces Medica...· 0 citations
B
ACKGROUND:
the optimal treatment strategy for patients with rectal cancer who achieve a complete or nearcomplete clinical response after neoadjuvant chemoradiotherapy is challenging.
AIM: to assess oncological outcomes after neoadjuvant chemoradiotherapy followed by total mesorectumectomy (TME) or local ex...
V. V. Cherepahina, M. Alekseev, E. G. Rybakov et al.· Koloproktologia· 0 citations
BACKGROUND
The interval from radiotherapy completion to surgery may affect pelvic fibrosis, operative difficulty, postoperative morbidity, and quality of rectal cancer resection. In total neoadjuvant therapy (TNT), however, this interval has different clinical content according to treatment sequence. We evaluated wheth...
José M. Aguilar-Romero, I. Vela-Sarmiento, L. Lino-Silva et al.· Journal of Surgical Oncology· 0 citations
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies
Neoadjuvant chemoradiotherapy (nCRT) followed by surgery is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, the optimal interval between nCRT completion and surgery remains undetermined, particularly rega...
Xu Huang, Fangyi Liu, Han Tang et al.· Diseases of the esophagus· 0 citations
Although neoadjuvant immunochemotherapy (NCIT) has shown promising prospects in the treatment of locally advanced esophageal squamous cell carcinoma (LA-ESCC), the role of adjuvant radiotherapy in these patients remains unclear.
This study aimed to investigate the impact of postoperative adjuvant radiotherap...
Li Li, X. Jing, Ming-Juan Sun et al.· Therapeutic Advances in Medi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.